Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...
Companies that have broken ground or begun construction on US manufacturing sites will be exempt from these tariffs.
Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...
The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic ...
A new report from Reuters 1 details how the residents of Kalundborg, Denmark, are reacting to the news of the looming layoffs ...
Harmony Biosciences reveals disappointing results from the Phase III Reconnect study of ZYN002 for Fragile X Syndrome, ...
Glenmark partners with Hengrui Pharma to develop Trastuzumab Rezetecan, enhancing its oncology pipeline and addressing unmet ...
In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the ...
Ascletis Pharma reveals ASC47, a promising weight loss drug, shows over 56% greater body weight reduction when combined with ...
Pharma leaders embrace direct-to-consumer strategies, with 94% exploring DTC programs to enhance patient experience and ...
Eli Lilly halted a study on bimagrumab for Type 2 diabetes patients, focusing on weight loss and muscle mass preservation.
Investors may not be convinced about the danger of Tylenol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback